Poor uterine development in Turner syndrome with oral oestrogen therapy.
OBJECTIVE
To evaluate uterine development in Turner syndrome (TS) patients in relation to treatment with oral ethinyl oestradiol (E2 ) for pubertal induction.


METHODS
Pelvic ultrasound data for 96 TS patients scanned since 1989 were analysed. Patients were classified into three groups: (1) untreated (n = 48); (2) complete spontaneous puberty (n = 10); and (3) treated with ethinyl oestradiol (n = 38). Uterine development was described in the three groups and compared with the normal data.


METHODS
Uterine length, fundal-cervical ratio (FCR) and shape were recorded, and presence or absence of ovaries noted. In the treated group, cross-sectional and longitudinal data were combined to compare uterine development with Tanner breast stage.


RESULTS
In untreated girls up to age 10 years there was a variable distribution of uterine length and FCR about the mean. Thereafter, the uterus failed to grow and mature normally. Girls with complete spontaneous puberty had morphologically normal ovaries and uteri, but of 7 girls who attained menarche, 3 subsequently developed secondary oligomenorrhoea or amenorrhoea. In the treated group, in general, breast development and uterine length progressed with increasing E2 dose. However, only 50% of girls with complete secondary sexual development had a mature heart-shaped uterine configuration.


CONCLUSIONS
Our current E2 treatment regimen for TS girls gives rise to satisfactory pubertal induction and maintenance, but failed to induce a fully mature uterus in half the cohort. In view of the high risk of miscarriage in TS in both spontaneous and assisted pregnancies, the effect of more physiological methods of E2 replacement on uterine development should be investigated.
Paterson
Wendy F
WF
Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, Scotland, UK. gcl354@clinmed.gla.ac.uk3
Hollman
Anne S
AS
Donaldson
Malcolm D C
MD
D000293:Adolescent; D001940:Breast / Q000254:growth & development; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D045166:Estradiol Congeners / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007621:Karyotyping; D008137:Longitudinal Studies; D011627:Puberty; D016896:Treatment Outcome; D014424:Turner Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*; D014599:Uterus / Q000254:growth & development*
D045166:Estradiol Congeners; D004997:Ethinyl Estradiol